# Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

> **NCT02324673** · PHASE1,PHASE2 · COMPLETED · sponsor: **INSYS Therapeutics Inc** · enrollment: 61 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Cannabidiol Oral Solution

## Key facts

- **NCT ID:** NCT02324673
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-13
- **Primary completion:** 2016-05-09
- **Final completion:** 2016-05-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324673, "Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02324673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*